Media headlines about BioTelemetry (NASDAQ:BEAT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioTelemetry earned a news impact score of 0.16 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.0954534825026 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
BioTelemetry (NASDAQ BEAT) opened at $33.55 on Friday. BioTelemetry has a one year low of $21.60 and a one year high of $39.20. The company has a market capitalization of $1,090.00, a price-to-earnings ratio of 25.61, a P/E/G ratio of 1.49 and a beta of 0.53. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75.
BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The company had revenue of $81.02 million for the quarter, compared to analyst estimates of $82.10 million. During the same period in the previous year, the firm earned $0.21 earnings per share. The company’s revenue for the quarter was up 52.7% compared to the same quarter last year. analysts anticipate that BioTelemetry will post 0.83 earnings per share for the current fiscal year.
Several research firms recently commented on BEAT. Raymond James Financial began coverage on BioTelemetry in a research note on Thursday, October 26th. They set an “outperform” rating and a $37.00 target price for the company. SunTrust Banks began coverage on BioTelemetry in a research note on Monday, October 23rd. They set a “buy” rating and a $41.00 target price for the company. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 2nd. Dougherty & Co reissued a “buy” rating and set a $40.00 target price on shares of BioTelemetry in a research note on Wednesday, November 8th. Finally, BidaskClub raised BioTelemetry from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $42.86.
ILLEGAL ACTIVITY WARNING: This news story was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.truebluetribune.com/2018/01/21/biotelemetry-beat-getting-somewhat-favorable-media-coverage-analysis-finds.html.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.